Phaseline

Targets › CASP9

CASP9 (Caspase-9): drug programs, companies and trials

3 programs from 2 companies in 6 trials: 6 Phase 1; Oncology; next expected readout May 2029.

Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates effector caspases caspase-3 (CASP3) or caspase-7 (CASP7). (UniProt, P55211)

Open in Phaseline: the race on CASP9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baylor College of MedicineAP1903
Caspase-9 activator/dimerizer drug that triggers apoptosis in iCaspase9-transduced T cells
CASP9Phase 1Acute Lymphoblastic LeukemiaMay 2029
Baylor College of MedicineiCaspase9-transduced T cells
Caspase-9 suicide gene-modified donor T cells for allogenic stem cell transplantation; iCa
CASP9Phase 1Acute Lymphoblastic LeukemiaMay 2029
Bellicum PharmaceuticalsBPX-501 T cells (rivogenlecleucel)
T cells transduced with CaspaCIDe safety switch (inducible caspase-9)
CASP9Phase 1Acute Lymphoblastic Leukemia; Leukemia; Hematologic MalignancyOct 2032

Conditions

Acute Lymphoblastic Leukemia (4) Leukemia (1) Hematologic Malignancy (1)

Modalities

mixed (3)

Companies

Baylor College of Medicine (2) Bellicum Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.